Xenon Pharmaceuticals
XENE
35 hedge funds and large institutions have $31.1M invested in Xenon Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
20% more capital invested
Capital invested by funds: $25.9M → $31.1M (+$5.23M)
9% more funds holding
Funds holding: 32 → 35 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15.59% less ownership
Funds ownership: 50.87% → 35.28% (-16%)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
+$1.4M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$232K |
| 3 |
Renaissance Technologies
New York
|
+$144K |
| 4 |
DMK
David M. Knott
|
+$77.3K |
| 5 |
SIM
Spark Investment Management
New York
|
+$46.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$10.6M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$970K |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$438K |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$259K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$38.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Spark Investment Management
New York
| $62K | +$46.9K | +12,700 | New |
|
|
27
Stifel Financial
St. Louis,
Missouri
| $58K | -$38.2K | -10,325 | -47% |
|
28
Dimensional Fund Advisors
Austin,
Texas
| $54K | – | – | – |
|
|
O
29
OppenheimerFunds
New York
| $54K | +$40.7K | +11,005 | New |
|
|
IVM
30
InterWest Venture Management
San Francisco,
California
| $23K | – | – | – |
|
31
Bank of Montreal
Toronto,
Ontario, Canada
| $16K | +$12.1K | +3,280 | New |
|
|
CSS
32
Cubist Systematic Strategies
Stamford,
Connecticut
| $11K | +$7.76K | +2,100 | +2,100% |
|
33
Morgan Stanley
New York
| $8K | -$32K | -8,668 | -84% |
|
34
Citigroup
New York
| $3K | – | – | – |
|
35
Wells Fargo
San Francisco,
California
| $2K | -$7.45K | -2,014 | -82% |
|
36
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$24K | -8,719 | Closed |
|
37
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$9K | -3,300 | Closed |
|
|
FDCDDQ
38
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$113 | -40 | Closed |
|
XENE Hedge Fund Activity: Q1 2018 in Review
35 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2018, worth a combined $31.1M — up 20% from $25.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new XENE positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 9 trimmed.
The largest buyer was Nexthera Capital, opening a new position worth an estimated $1.4M. The largest seller was BVF Inc, cutting an estimated $10.6M.
- 35 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2018, up from 32 in Q4 2017.
- Funds reported $31.1M of Xenon Pharmaceuticals stock for Q1 2018, up 20% quarter-over-quarter.
- 6 funds opened new Xenon Pharmaceuticals positions in Q1 2018 and 3 closed out, a net change of +3 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2018 was Nexthera Capital, an estimated $1.4M added.
- The largest Xenon Pharmaceuticals seller in Q1 2018 was BVF Inc, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2018.